Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study)

Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, März W

Plasma asymmetrical dimethylarginine (ADMA) was measured in 3,238 LURIC participants (2,543 with and 695 without angiographic coronary artery disease) and related to mortality over 5.45 years of median follow-up. The highest ADMA quartile showed adjusted hazard ratios of 1.87 for all-cause and 1.81 for cardiovascular mortality versus the lowest quartile. ADMA independently predicted mortality in CAD patients beyond established risk factors but not in those without angiographic disease.

Clinical Chemistry, 21. Dezember 2006 | PMID 17185364